Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 1999

View Archived Issues

1999 annual report reflects progress in clinical trials at Ono

New distamycin derivatives developed at Pharmacia & Upjohn for cancer Rx

Warner-Lambert discloses another series of anticoagulants

Ion channel-blocking antiarrhythmic and anesthetic agents from Nortran

First macrolide LHRH antagonists patented by Abbott

H. pylori vaccine comprising a chimeric protein designed by Korean scientists

Fatty acid analogues synthesized at Searle particularly useful for HIV infection

Novel 2-naphthylcarbapenems active against resistant staphylococci and Gram-negative pathogens

Collagenase-selective MMP inhibitors designed by British Biotech for arthritis

Investigational NNRTI proves safe and effective in early clinical trial in HIV-infected patients

Once-daily s.c. T-1249 may provide therapeutic levels in man according to animal data

In search of therapeutic alternatives for HIV resistance: in vitro studies with tipranavir

AGN-192024 is better than latanoprost for lowering diurnal IOP

Dainippon Ink & Chemicals begins clinical testing of allergy drug

Mycophenolate mofetil in the treatment of refractory uveitis

More promising results with abarelix in endometriosis

Leptin promotes weight loss in obese and lean adults

Glaxo Wellcome withdraws antibiotic due to safety concerns

Sanofi-Synthelabo discovers a promising new lead in the treatment of multiple sclerosis

Tamiflu approved in time for U.S. flu season

Vical receives orphan drug status for Allovectin-7

Positive results reported for Amylin's type II diabetes therapy

Scios begins patient enrollment in phase III Natrecor trial

Additional positive data reported for Cell Pathways' exisulind

CPMP gives favorable opinion on Taxotere for advanced non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...